NCT00515697View on ClinicalTrials.gov

A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Metastatic Renal Cell Carcinoma
Interventions
BIOLOGICAL

Ramucirumab

Ramucirumab is an injectable solution administered as an intravenous infusion over 1 hour at a dose of 8 mg/kg day 1 of every 14-day cycle.

Trial Locations (11)

14263

ImClone Investigational Site, Buffalo

19026

ImClone Investigational Site, Drexel Hill

19111

ImClone Investigational Site, Philadelphia

44195

ImClone Investigational Site, Cleveland

60637

ImClone Investigational Site, Chicago

70006

ImClone Investigational Site, Metairie

76012

ImClone Investigational Site, Arlington

94115

ImClone Investigational Site, San Francisco

98109

ImClone Investigational Site, Seattle

02115

ImClone Investigational Site, Boston

08822

ImClone Investigational Site, Flemington

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT00515697 - A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter